Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients.
Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four patients. These effects are most likely related to loreclezole, as doses and plasma levels of the associated anti-epileptic drugs remained unchanged during the study. Loreclezole was tolerated well and no changes in haematological or biochemical parameters were observed.
Rentmeester
T
T
Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands.
Hulsman
J
J
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
D000927:Anticonvulsants; D014230:Triazoles; C066440:loreclezole